Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models

BACKGROUND: Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Piao, Yuji, Park, Soon Young, Henry, Verlene, Smith, Bryan D., Tiao, Ningyi, Flynn, Daniel L., de Groot, John F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Basic and Translational Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998992/
https://ncbi.nlm.nih.gov/pubmed/26965451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now030
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky